Recently, Canadian, US and European health regulatory agencies issued warnings about an increased risk of stroke and death in elderly patients with dementia receiving atypical antipsychotics. Assessing both randomised and nonrandomised evidence, this systematic review found conflicting findings, particularly for risperidone. More research is needed to better inform clinical practice.
Keywords: Neuroleptics, typical antipsychotics, atypical antipsychotics, dopamine, dementia, cerebrovascular events
Rights & PermissionsPrintExport